- Home
- BASE vs GKOS Comparison
BASE vs GKOS Comparison
Compare BASE & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BASE
- GKOS
- Stock Information
- Founded
- BASE 2011
- GKOS 1998
- Country
- BASE United States
- GKOS United States
- Employees
- BASE N/A
- GKOS N/A
- Industry
- BASE EDP Services
- GKOS Medical/Dental Instruments
- Sector
- BASE Technology
- GKOS Health Care
- Exchange
- BASE Nasdaq
- GKOS Nasdaq
- Market Cap
- BASE N/A
- GKOS 5.1B
- IPO Year
- BASE 2021
- GKOS 2015
- Fundamental
- Price
- BASE $17.76
- GKOS $89.91
- Analyst Decision
- BASE Buy
- GKOS Strong Buy
- Analyst Count
- BASE 15
- GKOS 13
- Target Price
- BASE $21.07
- GKOS $135.15
- AVG Volume (30 Days)
- BASE 757.6K
- GKOS 1.1M
- Earning Date
- BASE 06-04-2025
- GKOS 04-30-2025
- Dividend Yield
- BASE N/A
- GKOS N/A
- EPS Growth
- BASE N/A
- GKOS N/A
- EPS
- BASE N/A
- GKOS N/A
- Revenue
- BASE $209,466,000.00
- GKOS $404,523,000.00
- Revenue This Year
- BASE $12.08
- GKOS $27.84
- Revenue Next Year
- BASE $13.60
- GKOS $27.88
- P/E Ratio
- BASE N/A
- GKOS N/A
- Revenue Growth
- BASE 16.35
- GKOS 23.92
- 52 Week Low
- BASE $12.78
- GKOS $77.10
- 52 Week High
- BASE $28.67
- GKOS $163.71
- Technical
- Relative Strength Index (RSI)
- BASE 62.15
- GKOS 45.80
- Support Level
- BASE $17.02
- GKOS $84.26
- Resistance Level
- BASE $18.15
- GKOS $92.27
- Average True Range (ATR)
- BASE 0.67
- GKOS 3.94
- MACD
- BASE 0.12
- GKOS 0.57
- Stochastic Oscillator
- BASE 85.73
- GKOS 58.87
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.